Lung Cancer

Immunotherapy Benefits Select Patients With Late-Stage NSCLC

By

John Schieszer

Publish Date April 8, 2022

A systematic review revealed characteristics that may help clinicians predict which patients will benefit from immunotherapy.

Biosimilars as Effective as Reference Biologics for Cancer Treatment

By

Carina Storrs, PhD

Publish Date March 16, 2022

The biosimilars proved as effective as the original biologics in all cancers studied.

Many Immune Checkpoint Inhibitor Combination Therapies Show No Evidence of Drug Synergy

By

Victoria Forster, PhD

Publish Date March 14, 2022

The efficacy of many combination therapies may be due to independent drug action, not synergistic or additive effects.

Rate of CRT-Related Pneumonitis in NSCLC May Be Higher in Real World Than in Clinical Trials

The pooled incidence of chemoradiation-induced grade 3-5 pneumonitis was 3.62% in randomized trials, 5.98% in observational studies, and 7.85% in observational studies of platinum doublet chemotherapy.

Chemo-Immunotherapy May Have Edge in Advanced NSCLC With Higher PD-L1

Results showed a median overall survival of 25.0 months for chemo-immunotherapy vs 20.9 months for immunotherapy alone.

Adagrasib Promising in KRAS^G12C-Mutated NSCLC

The researchers noted that responses were deep, with 75% of responders achieving a greater than 50% tumor reduction.

Amivantamab-Lazertinib Active in EGFR-Mutant NSCLC After Exhausting Standard Care Options

The overall response rate was 33%, with 1% of patients having complete responses and 32% having partial responses.

More African-Americans Screened for Lung Cancer With USPSTF 2021 Criteria

After implementation of the USPSTF 2021 criteria for lung cancer screening, there was an increase in the proportion of African-American individuals who underwent screening.